Diamedica Therapeutics Inc SEC Filings

DiaMedica Therapeutics Inc. (DMAC) filed a Form S-8 registering 1,000,000 common shares for issuance under its 2021 Employment Inducement Incentive Plan.

The Board amended the plan on July 31, 2025 to reserve an additional 1,000,000 shares for equity awards to individuals who were not previously employees or directors, as an inducement to employment under Nasdaq Listing Rule 5635(c)(4). The plan allows stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock-based awards.

DiaMedica Therapeutics (DMAC) filed its Q3 2025 10-Q, highlighting a clinical-stage focus on DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). For the nine months ended September 30, 2025, the company reported a net loss of $24.0 million and used $21.3 million in operating cash. As of September 30, 2025, cash, cash equivalents and marketable securities were $55.3 million, with working capital of $51.0 million.

R&D expenses were $6.4 million in Q3 (up from $5.0 million a year ago) and G&A was $2.6 million (up from $1.9 million), reflecting ongoing ReMEDy2 trial activities and PE program work. The company completed a July 2025 private placement of 8,606,425 shares at $3.50 for $30.1 million gross (~$30.0 million net) and sold 223,472 shares via its ATM for $1.6 million gross; up to $100 million may be sold under the ATM, with $98.4 million remaining as of quarter end.

In PE, interim Phase 2 results (N=28) showed DM199 appeared safe with blood pressure reductions. In AIS, ReMEDy2 site activations and enrollment remain slower than expected; interim analysis is estimated in the second half of 2026, and UK approval to conduct the study was received on August 28, 2025.

DiaMedica Therapeutics (DMAC) reported a Form 4 for its Chief Marketing Officer showing a grant of stock options to purchase 450,000 shares at an exercise price of $4.58 per share on 08/11/2025. The options expire on 08/10/2035 and were reported as directly owned following the transaction.

The filing states a time-based vesting schedule: 112,500 options vest on the one-year anniversary of the grant date, and the remaining 337,500 vest in twelve equal quarterly installments starting three months after that one-year mark, conditioned on continued service.

DiaMedica Therapeutics Inc. (DMAC) filed a Form 3 initial statement of beneficial ownership for its Chief Marketing Officer. The filing states that no securities are beneficially owned. The event date was 08/11/2025.

The form was signed by attorney-in-fact Joshua L. Colburn pursuant to a Power of Attorney. This is a routine administrative disclosure and does not report any transactions.

Insider purchases increased a single beneficial stake to 7,764,465 shares of DiaMedica Therapeutics (DMAC). From August 13 to August 27, 2025, a series of open-market purchases totaling multiple transactions were reported, with individual purchase sizes ranging from 8,233 to 338,265 shares at per-share prices between $5.8573 and $6.00. The shares are owned directly by Trill AB and indirectly by Jan Stahlberg, a company director and 10% owner, who "has the sole power to vote and dispose" of the shares. The Form 4 shows continued accumulation over a two-week period via multiple purchases, and the filing is signed by Jan Stahlberg and by him as Board Member of Trill AB.

DiaMedica Therapeutics Inc. Schedule 13G/A shows that Trill AB and its board member Jan Stahlberg report beneficial ownership of 7,764,465 common shares, representing 15.02% of DiaMedica's outstanding common stock (based on 51,688,913 shares outstanding as of August 8, 2025). The filing identifies Trill AB as the record holder and Mr. Stahlberg as a beneficial owner and board member. The reported holdings reflect shared voting and shared dispositive power of 7,764,465 shares for each reporting person, with no sole voting or dispositive power. The filing includes a certification that the shares were not acquired to change or influence control of the issuer.

DiaMedica Therapeutics Inc. (DMAC) received a Schedule 13G disclosing that Leon G. Cooperman may be deemed the beneficial owner of 3,110,220 Voting Common Shares, representing approximately 6.0% of the company's outstanding common shares. That total comprises 2,450,000 shares held directly by Mr. Cooperman and 660,220 shares held directly by The Leon and Toby Cooperman Foundation.

The filing states the ownership percentage is calculated using 51,688,913 shares outstanding as of August 8, 2025, per the issuer's quarterly report. The statement affirms the shares were not acquired to change or influence control of the issuer and lists Edward Levy signing as attorney-in-fact on behalf of Mr. Cooperman.

DiaMedica Therapeutics Inc. entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell, from time to time, up to $100.0 million of its common shares through an at-the-market program. TD Cowen will act as sales agent and may receive compensation of up to 3.0% of gross proceeds. Sales are to be made under the company’s Form S-3 shelf registration and may not occur until that registration is declared effective. The agreement contains customary representations, indemnities, and incorporated legal opinions from Pushor Mitchell and Alston & Bird.

DiaMedica Therapeutics filed a shelf registration to offer up to $100,000,000 of common shares, warrants and units and a sales agreement permitting up to $100,000,000 of common shares to be sold from time to time under an agreement with TD Securities (USA) LLC. The company’s lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of KLK1 being developed for preeclampsia (PE) and acute ischemic stroke (AIS); DM199 holds Fast Track designation for AIS and avoids human/animal tissue sourcing.

Clinical progress includes an interim Phase 2 investigator-sponsored PE result (N=28) reporting safe, well-tolerated profiles, rapid, statistically significant reductions in blood pressure sustained up to 24 hours post-infusion and no evidence of placental transfer. DiaMedica plans a U.S. IND submission in the second half of 2025. The Phase 2/3 ReMEDy2 AIS trial is adaptive (target ~300, maximum up to 728 after interim analysis of 200) but is experiencing slower-than-expected site activation and enrollment; the company is expanding internal capabilities and global site filings to mitigate delays.